Compare FHB & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHB | RCUS |
|---|---|---|
| Founded | 1858 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.9B |
| IPO Year | 2016 | 2018 |
| Metric | FHB | RCUS |
|---|---|---|
| Price | $27.41 | $23.10 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 7 | 10 |
| Target Price | $27.00 | ★ $31.90 |
| AVG Volume (30 Days) | ★ 1.3M | 789.7K |
| Earning Date | 04-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | ★ 22.91 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $880,788,000.00 | $247,000,000.00 |
| Revenue This Year | $7.00 | N/A |
| Revenue Next Year | $3.56 | $45.62 |
| P/E Ratio | $49.53 | ★ N/A |
| Revenue Growth | ★ 8.94 | N/A |
| 52 Week Low | $22.65 | $7.92 |
| 52 Week High | $28.35 | $28.72 |
| Indicator | FHB | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 56.48 | 41.55 |
| Support Level | $26.05 | $20.20 |
| Resistance Level | $27.74 | $24.33 |
| Average True Range (ATR) | 0.53 | 1.34 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 78.71 | 2.92 |
First Hawaiian Inc is a bank holding company. It provides a diversified range of banking services to consumer and commercial customers, including deposit products, lending services, and wealth management and trust services. The company offers a variety of deposit products to its customers, including checking and savings accounts and other types of deposit accounts. It provides commercial and industrial lending, including auto dealer flooring, commercial real estate, and construction lending. It also offers comprehensive consumer lending services focused on residential real estate lending, indirect auto financing, and other consumer loans. The company's segments are Retail Banking, Commercial Banking, and Treasury, and others of which key revenue is derived from Retail Banking.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.